We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Consider Buying Flowserve (FLS) Now
Read MoreHide Full Article
Flowserve Corporation (FLS - Free Report) is well-poised to benefit, driven by its solid product portfolio, strong backlog level and investments in enhancing organic growth.
The company currently carries a Zacks Rank #2 (Buy).
Price Performance
Shares of Flowserve have gained 23.7%, outperforming the industry’s growth of 17.5% in the past three months. Meanwhile, the S&P 500 Index has rallied 11.7% in the same timeframe.
Below we discussed why it is worth investing in the company.
Multiple Tailwinds: Though the coronavirus outbreak-led uncertainties are concerning, Flowserve’s solid backlog will likely prove to be beneficial in the quarters ahead. For instance, exiting first-quarter 2020, its backlog stood at $2.18 billion, reflecting an increase of 1.2% on a sequential basis. Also, the company primarily invests funds in enhancing organic growth and Flowserve 2.0, a multi-year transformation program. Notably, Flowserve 2.0 is likely to improve the company's ability to effectively support customers and drive significant long-term value for shareholders.
Liquidity Position: The company’s solid liquidity position allows it to cover its immediate liabilities. Notably, at the end of the first quarter, it had available liquidity of more than $1.3 billion, comprising of cash and cash equivalents of about $622 million, and $721 million of available capacity under its revolving credit facility. Also, some of the company’s actions, including the reduction of discretionary expenses and the re-prioritization of capital expenditure, will likely help it to maintain a healthy margin performance amid the coronavirus crisis.
In addition, it remains committed toward rewarding shareholders handsomely. Notably, in the first quarter, it paid out dividends of $26 million and repurchased shares worth $32.1 million.
Estimate Trend: In the past 60 days, analysts have increasingly become bullish on the company, as evident from upward earnings estimate revisions. Notably, the Zacks Consensus Estimate for its 2020 earnings has trended up from $1.41 to $1.43 on one upward estimate revision against none downward. In addition, over the same timeframe, the consensus estimate for 2021 earnings has trended up from $1.43 to $1.44 on one upward estimate revision against none downward.
Altra Industrial delivered an earnings surprise of 9.78%, on average, in the trailing four quarters.
Chart Industries delivered an earnings surprise of 1.41%, on average, in the trailing four quarters.
Middleby delivered an earnings surprise of 7.54%, on average, in the trailing four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Here's Why You Should Consider Buying Flowserve (FLS) Now
Flowserve Corporation (FLS - Free Report) is well-poised to benefit, driven by its solid product portfolio, strong backlog level and investments in enhancing organic growth.
The company currently carries a Zacks Rank #2 (Buy).
Price Performance
Shares of Flowserve have gained 23.7%, outperforming the industry’s growth of 17.5% in the past three months. Meanwhile, the S&P 500 Index has rallied 11.7% in the same timeframe.
Below we discussed why it is worth investing in the company.
Multiple Tailwinds: Though the coronavirus outbreak-led uncertainties are concerning, Flowserve’s solid backlog will likely prove to be beneficial in the quarters ahead. For instance, exiting first-quarter 2020, its backlog stood at $2.18 billion, reflecting an increase of 1.2% on a sequential basis. Also, the company primarily invests funds in enhancing organic growth and Flowserve 2.0, a multi-year transformation program. Notably, Flowserve 2.0 is likely to improve the company's ability to effectively support customers and drive significant long-term value for shareholders.
Liquidity Position: The company’s solid liquidity position allows it to cover its immediate liabilities. Notably, at the end of the first quarter, it had available liquidity of more than $1.3 billion, comprising of cash and cash equivalents of about $622 million, and $721 million of available capacity under its revolving credit facility. Also, some of the company’s actions, including the reduction of discretionary expenses and the re-prioritization of capital expenditure, will likely help it to maintain a healthy margin performance amid the coronavirus crisis.
In addition, it remains committed toward rewarding shareholders handsomely. Notably, in the first quarter, it paid out dividends of $26 million and repurchased shares worth $32.1 million.
Estimate Trend: In the past 60 days, analysts have increasingly become bullish on the company, as evident from upward earnings estimate revisions. Notably, the Zacks Consensus Estimate for its 2020 earnings has trended up from $1.41 to $1.43 on one upward estimate revision against none downward. In addition, over the same timeframe, the consensus estimate for 2021 earnings has trended up from $1.43 to $1.44 on one upward estimate revision against none downward.
Other Key Picks
Some other top-ranked stocks from the same space are Altra Industrial Motion Corp. , Chart Industries, Inc. (GTLS - Free Report) and The Middleby Corporation (MIDD - Free Report) . All the companies currently carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Altra Industrial delivered an earnings surprise of 9.78%, on average, in the trailing four quarters.
Chart Industries delivered an earnings surprise of 1.41%, on average, in the trailing four quarters.
Middleby delivered an earnings surprise of 7.54%, on average, in the trailing four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>